Challenges, Opportunities, and Evolving Landscapes in Pharmacogenomics and Personalized Medicine -- Implementation of Pharmacogenomic Sample Collection in Clinical Trials -- Pharmacogenomics -- Applications of Pharmacogenomics in Drug Discovery -- Applications of Pharmacogenomics in Clinical Trials -- Pharmacogenomics Applications in Drug Metabolism -- The Genetics of Adverse Drug Reactions -- Strategies and Resources for Marker Selection and Genotyping in Genetic Association Studies -- Study Design and Statistical Issues in Pharmacogenetics Research -- Holy SNP, Batman! -- Predictive Biomarker Classifiers in the Design of Pivotal Clinical Trials -- Translation of Biomarkers into Clinical Utility -- Pharmacogenomic Study Feasibility Assessment and Pharmaceutical Business Decision-Making -- Co-Development of Drugs and Pharmacogenomics-Based Diagnostics in Oncology -- Pharmacogenomics Applications in Epilepsy Chantal Depondt -- Pharmacogenomics in Alzheimer's Disease -- Pharmacogenomics Applications in Psychiatric Disorders -- Pharmacogenomics in HIV Disease -- Pharmacogenomics and Cardiovascular Drugs -- Pharmacogenomic Applications in Children -- Pharmacogenomics of Rare and Monogenic Disorders.

With all of the multitude of challenges facing the pharmaceutical research and development process, the industry is actively exploring the relationships between human genetics and drug responsiveness, susceptibility to disease and disease severity. In Pharmacogenomics and Personalized Medicine, leading experts from the pharmaceutical industry, the scientific community and the government provide guidance for conducting pharmacogenomic research from discovery to the market, while also presenting a realistic perspective on the challenges, practicalities and obstacles in its application. Focusing on DNA data and associated analytical methodologies this volume includes a wide array of vital, cutting-edge research. Comprehensive and timely, Pharmacogenomics and Personalized Medicine will assist novice and experienced investigators alike in the understanding of the current scientific challenges in applying pharmacogenomics to drug discovery and clinical development.